Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
FT819 manufacturing: Fate uses a clonal master cell bank approach for its off-the-shelf CD8 CAR T, claiming a single bank could yield 10 million doses and the current facility could produce ~50,000 doses by increasing staffing, with cost of goods ~ $3,000 per dose at 100-liter scale. Clinical strategy and lupus focus: FT819 was engineered with reduced signaling (mutated CD3? ITAMs) to prioritize safety—reported no ICANS or GVHD and low-grade CRS—and, after modest durability in high-burden DLBCL (~40% CR), Fate is advancing a potential registration-enabling Phase II single-arm trial in lupus nephritis in 2H while already observing meaningful outpatient-administered patient improvements. Next-generation programs: Fate is developing multiplex-edited candidates (notably FT839 ) in a "Sword and Shield" strategy designed to eliminate conditioning and broaden activity by targeting CD19 and CD38 with intact CD3? for greater potency. Interested in Fate Therapeutics, Inc.? Here are five
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t NoticedGlobeNewswire
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
FATE
Earnings
- 11/13/25 - Beat
FATE
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/16/26 - Form 4
- FATE's page on the SEC website